Merus Multiclonics®

Our Multiclonics® therapeutics are produced from our proprietary technology platforms, which are able to generate a diverse array of antibody binding domains against virtually any target. Multiple binding domains can be combined to produce novel bispecific and trispecific antibodies, using our Biclonics® and Triclonics® platforms.

These platforms allow us to functionally evaluate our antibodies by generating large numbers of diverse panels of antibodies and to functionally screen them at high throughput to lead to the discovery of therapeutic candidates with unique and innovative properties. Further, by creating antibodies that bind to multiple targets, Biclonics® and Triclonics® may be designed to have a variety of mechanisms of action against cancer, including blocking tumor cell growth and survival and mobilizing a patient’s immune response to fight cancer. Biclonics® can also be conjugated with a range of linkers and payloads to generate antibody-drug conjugates (ADClonicsTM) capable of binding two different targets with the potential for improved binding selectivity, internalization and cancer cell killing activity.

Distinctive Characteristics of Multiclonics® Deliver Unique Functionality

Unique Functionality

Our Multiclonics® have been shown to retain the qualities of natural human, full-length immunoglobulin G (IgG) antibodies, including stability, long half-life and low immunogenicity.

Biclonics® are differentiated from many other bispecific antibody formats because they do not require linkers or modifications to force correct pairing of heavy and light chains nor do they require fusion proteins to add functionality. With the IgG format of natural antibodies, Biclonics® can be reliably manufactured with high yields.

Triclonics® have a unique antibody design capable of simultaneously binding three targets at once. Triclonics® have the potential to enable tumor cell-killing activity and/or to modulate the immune system to promote more robust and specific anti-tumor immune responses.


Our Multiclonics® platforms provide patented means for efficient discovery, screening and identification of multispecific antibodies capable of differentiated biology having novel target combinations and activity.


Biclonics® bispecific antibodies are capable of binding two different targets in cis for dual cancer cell targeting or trans for bridging the cancer cell to an immune effector cell.


Triclonics® trispecific antibodies are capable of binding three different targets.


The Biclonics® format and platform is compatible with a range of linkers and payloads to generate antibody-drug conjugates (ADClonicsTM) capable of binding two different targets for improved selectivity and potency.

Multiclonics® Platforms

Our platforms use unbiased high throughput functional screening in molecular and cell-based assays to identify novel, innovative Biclonics® and Triclonics® antibodies. Our lead molecules are selected from up to thousands of candidates generated from these platforms, identifying those molecules that possess unique biology and specific characteristics for therapeutic application.

Multiclonics® at work

Watch how one of our unique mechanisms of actions works.
An example of the Biclonics® platform is zenocutuzomab (Zeno, MCLA-128), which utilizes our Dock & Block® mechanism to bind to HER2 and disrupt the interaction between HER3 and its ligand, NRG1. As with all of our Biclonics®, Zeno has a full-length IgG antibody format for tolerability, ease of administration and long half-life for convenient dosing schedules.

Scientific Publications

To read more about Merus platform and its leading Biclonics® technology, please follow the link below for access to scientific publications.

View Publications